New Elocta and Alprolix data

Swedish Orpahn Biovitrum (STO: SOBI) and Sanofi (Euronext: SAN) have presented further data to show that their drugs can provide perioperative hemostatic control across a wide spectrum of major and minor surgeries in patients of all ages with both severe hemophilia A and B.

Orthopedic surgery is common in hemophilia since a large majority of patients with the condition experience joint damage due to suboptimal levels of protection, leading to reoccurring bleeding in the joints.

But, of course, people with hemophilia are at risk during surgical procedures due to the increased chance of bleeding during the procedure and the reduced clotting of blood.